Navigation Links
Ironwood and Forest Present Additional Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation
Date:5/31/2009

-- Data Presented Today at DDW Demonstrate Linaclotide Provided Early Onset of Abdominal Pain Relief and Improved Bowel Habits --

CAMBRIDGE, Mass. and NEW YORK, May 31, 2009 /PRNewswire-FirstCall/ -- Ironwood Pharmaceuticals, Inc. and Forest Laboratories, Inc. (NYSE: FRX) today announced results from additional analyses of their Phase 2b study assessing the safety and efficacy of the novel, first-in-class agent linaclotide in 419 patients with irritable bowel syndrome with constipation (IBS-C). Previous analyses of these data indicated that once-daily oral dosing with linaclotide, across a range of doses, significantly improved abdominal symptoms, bowel habits, and global assessments over the 12-week treatment period. These additional analyses demonstrated that patients treated with linaclotide experienced a statistically significant improvement in abdominal symptoms, bowel habits, and global assessments within the first week of treatment. Results were presented today at the Digestive Disease Week (DDW) conference being held in Chicago from May 30 through June 4, 2009. The companies also will present additional data throughout the week from studies of linaclotide in patients with IBS-C or chronic constipation (CC).

(Logo: http://www.newscom.com/cgi-bin/prnh/20001011/FORESTLOGO )

(Logo: http://www.newscom.com/cgi-bin/prnh/20081006/NEM080ALOGO )

The data presented today in an oral presentation (Abstract 157: Effect of Linaclotide o
'/>"/>

SOURCE Forest Laboratories, Inc.; Ironwood Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Ironwood Announces Linaclotide European Licensing Agreement with Almirall
2. Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation
3. Ironwood and Collaborators Present Preclinical Data Demonstrating That Cyclic GMP Alleviates Intestinal Pain
4. Ironwood Raises $50 Million to Advance Linaclotide Through Phase 3
5. Ironwood and Forest to Present Positive Data From Linaclotide Phase 2b IBS-C Study at ACG Annual Scientific Conference
6. Ironwood Pharmaceuticals and Forest Laboratories Announce Presentation of Linaclotide Phase 2b Chronic Constipation Study Results
7. Forest Laboratories, Inc. and Laboratorios Almirall, S.A. Provide an Update on the Aclidinium Bromide Clinical Development Program
8. Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Positive Results of Phase III Study of Milnacipran for the Management of Fibromyalgia
9. Forest Laboratories, Inc. and Gedeon Richter Plc Announce Positive Phase II Results with the Investigational Antipsychotic Cariprazine in Patients with Acute Mania Associated with Bipolar I Disorder
10. Forest Laboratories Announces Positive Results from Phase III Clinical Studies of Ceftaroline for the Treatment of Complicated Skin and Skin Structure Infections
11. Forest and Almirall Announce Positive Results of Clinical Studies for Aclidinium Bromide, a Novel, Long-Acting Anticholinergic for the Treatment for COPD

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)..., LOVELAND,Colo.,Nov.25/PRNewswire-FirstCall/--...f advanceddiagnosticandspecialtyproductstothevete...agnosticsCorporationforthesupplyofbloodgasproducts..., (Logo: http://www.newscom.com/cgi-bin/prnh/200...passionforinnovatinginthefieldofadvancedpoint-of-c...
(Date:11/25/2009)..., PRINCETON,N.J.,Nov.25/PRNewswire-FirstCall/--...aceuticalcompanycommittedtodiscovering,developinga...reportedfinancialresultsforthefiscalyearendedSepte...illionincash,cashequivalentsandshortterminvestment...RG7128 ,, Phase2bTrial ,, InlateNovembe...
(Date:11/25/2009)..., CHICAGOandSTAFA,Switzerland,Nov.25/PRNewswire...rofinnovativehearingsolutions,presentedtheseconded...nthespecialneedsoftheolderpopulation.Theconference...omaroundtheworldandmorethan250clinicianswhoworkeve...ytoshareexperiencesanddiscussthelatestresearchandt...
Breaking Medicine Technology:Heska Announces Supply Agreement With Roche Diagnostics 2Heska Announces Supply Agreement With Roche Diagnostics 3Pharmasset Reports Fiscal Year End 2009 Financial Results 2Pharmasset Reports Fiscal Year End 2009 Financial Results 3Pharmasset Reports Fiscal Year End 2009 Financial Results 4Pharmasset Reports Fiscal Year End 2009 Financial Results 5Pharmasset Reports Fiscal Year End 2009 Financial Results 6Pharmasset Reports Fiscal Year End 2009 Financial Results 7Pharmasset Reports Fiscal Year End 2009 Financial Results 8Phonak Successfully Hosts Hearing Care for Adults 2009 Conference 2Phonak Successfully Hosts Hearing Care for Adults 2009 Conference 3FDA Acts to Protect Public Health from Electronic Cigarettes 52470 1FDA Acts to Protect Public Health from Electronic Cigarettes 52470 2FDA Acts to Protect Public Health from Electronic Cigarettes 52470 3Medifast Independent Director Lt Gen Dennis McCarthy Confirmed as Assistant Secretary of Defense for Reserve Affairs 52466 1Medifast Independent Director Lt Gen Dennis McCarthy Confirmed as Assistant Secretary of Defense for Reserve Affairs 52466 2Medifast Independent Director Lt Gen Dennis McCarthy Confirmed as Assistant Secretary of Defense for Reserve Affairs 52466 3Endologix Reports 42 25 Second Quarter 2009 Revenue Growth 52461 1Endologix Reports 42 25 Second Quarter 2009 Revenue Growth 52461 2Endologix Reports 42 25 Second Quarter 2009 Revenue Growth 52461 3Endologix Reports 42 25 Second Quarter 2009 Revenue Growth 52461 4Endologix Reports 42 25 Second Quarter 2009 Revenue Growth 52461 5Endologix Reports 42 25 Second Quarter 2009 Revenue Growth 52461 6Endologix Reports 42 25 Second Quarter 2009 Revenue Growth 52461 7Endologix Reports 42 25 Second Quarter 2009 Revenue Growth 52461 8
...rship Strengthened with Clinical Trials S...PANY, N.J. and ATLANTA, Sept. 6 Image Solutions,I...quire Zurich,Biostatistics, Inc. (ZBI). With the L...gulatory submissions, the acquisition further stre...Consortium (CDISC) capabilities,the FDA-supported ...
...tor to Enter Registration Trials, HAYWARD, Calif.... KOSN ) today announced that it has successfully,... Drug Administration,(FDA) on the design of its TI...s Hsp90 inhibitor tanespimycin as a treatment for ...Special Protocol Assessment (SPA),process, Kosan a...
Other Medicine Technology:Image Solutions, Inc. Acquires Zurich Biostatistics, Inc. 2Image Solutions, Inc. Acquires Zurich Biostatistics, Inc. 3Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma 2Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma 3Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma 4Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma 5Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma 6Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma 7
(Date:11/27/2009)...s to bring unprecedented medical, economic burdens...althDay News) -- The number of people with diabete...the next 25 years, a new study predicts. , That...on people with the disease, up from 23.7 million t... people with diabetes will triple, the study also ...
(Date:11/27/2009)... Voyant Health™ announced today... licensed its TraumaCad Enterprise orthopedic temp...solution. , (PRWEB) Novem...ay that Spectrum Health (Grand Rapids, Michigan) h...mplating solution and its TraumaCad Extend workflo...
(Date:11/27/2009)... Specialist manufacturers who use med... saving millions of dollars by bringing in technol...ncreasing numbers of pro-active medical manufactur...e concept stage of their projects, ensuring that p... processes or potentially outdated technology. , ...
(Date:11/26/2009)...ORK,Nov.27/PRNewswire/--Withcoldandfluseasonuponus...ontrolthespreadofinfectionsandavoidillness. ,, ...buttoavoidtransmittingillnessifwe,resick,"saidEile...nursingdirectorforinfectioncontrolandoccupationalh...,, HospitalforSpecialSurgeryhasoneofthelowestin...
(Date:11/26/2009)...t 25 years, the number of Americans living with di...llion in 2009 to 44.1 million in 2034. Over the sa..., rising from $113 billion to $336 billion, even w...archers based at the University of Chicago report ...number of those with diabetes covered by Medicare ...
Breaking Medicine News(10 mins):Health News:Diabetes Cases Expected to Double in 25 Years 2Health News:Diabetes Cases Expected to Double in 25 Years 3Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 2Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 3Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 2Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 3Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 4Health News:Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use 2Health News:Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use 3Health News:Diabetes cases to double and costs to triple by 2034 2Health News:Diabetes cases to double and costs to triple by 2034 3
...women demand epidurals during delivery even if not...atest demand of midwives through the experts at Ro... would help stem the// growing number of women ask...pidural though relieves pain during child birth, t...
...cer has acquired a new twist in its sordid journey...d upon “Stem Cells” and their involvement in the d...ation to say that stem cells may hold clues for la...his is probably the reason why a tumor resurfaces ...
... Vado Diomande, a childhood dancer, from the tende...“Mask Dance” has suffered a setback to his health....ts, as it was thought to be. // On Thursday,...etching the animal skins on drums for the purpose ...
...en are too busy building careers, and raking in th...babies that result in delayed motherhood, reveals ...very boring read, a loss of 92,000 babies each yea... of infertility. But Women seem to be stuck up on ...
...ew study appearing in the February 22 issue of the... no significant differences in the effectiveness o... or paclitaxel. Drug-releasing stents are known to...r the outcome of procedures like angioplasty, when...
...thwestern Memorial Hospital along with Northwester...ting a Phase II clinical trial to determine if ava...drug also known as bevacizumab is an anti-angiogen...adiation therapy and chemotherapy can reduce local...
Other Medicine News:Health News:Avastin under trial to test efficacy for pancreatic tumours! 2
...chairs with concave seats and large backrests with...backrests, armrests, and casters and glides. &bull...riety of environments including: industry, educati... care and office. • With reinforced nylon bas...
BEN/1Q-CAB-ERB - Reinforced Nylon Base - Model 1Q72-CAB-ERB
BEN/1Q-CAB-ERB - Reinforced Nylon Base - Model 1Q70-CAB-ERB
...chairs with concave seats and large backrests with...backrests, armrests, and casters and glides. &bull...riety of environments including: industry, educati... care and office. • With cast aluminum base &...
Medicine Products: